IMNM · Immunome, Inc.
$17.99
-1.48% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-7.3
Dividend yield
0.0%
Beta
2.56
Avg volume
1M
Employees
0K
Daily Change %
-1.48%
5 Days Change
10.87%
10 Days Change
3.87%
30 Days Change
-24.67%
60 Days Change
-34.81%
Month to Day Change
-12.59%
Year to Day Change
-14.99%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMNM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
Barclays
Overweight$36.00
+100.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-01 | Stifel | Initiates | Hold | $0.00 → $24.00 |
| 2026-09-21 | Alliance Global Partners | Initiates | Buy | $0.00 → $32.00 |
| 2026-09-10 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-08-12 | Truist Securities | Maintains | Buy | $37.00 → $38.00 |
| 2026-08-12 | Wedbush | Maintains | Outperform | $31.00 → $35.00 |
| 2026-07-21 | Wedbush | Reiterates | Outperform | $31.00 |
| 2026-06-12 | Wedbush | Reiterates | Outperform | $31.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 23.1% below the 50-day MA ($23.40).
- bearish: Price vs 200-day MA: Trading 20.2% below the 200-day MA ($22.55).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.14) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($15.24) and high ($29.83).
IMNM Price Chart
Loading chart for IMNM…
Fundamentals
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.